RxDoctor Payments Data

Christopher Thiagarajah, MD

Ophthalmic Plastic and Reconstructive Surgery · Edwards, CONPI 1952435919

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $44,600 of the $56,136 with a category attached, or 79.4%. Amgen accounts for 99.0% of it on its own, with 5 other manufacturers making up the rest. Among ophthalmic plastic and reconstructive surgery clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$56,136in general payments, 2019–2025

Across 101 payments — averaging $555.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$56K
  • AbbVie$337
  • Coopervision Inc.$112
  • Eyevance Pharmaceuticals LLC$47
  • Conmed Corporation$38
  • Sun Pharmaceutical Industries Inc.$20

What the payments were for

  • Consulting fees$5,1009%
  • Speaking & faculty fees$44,60079%
  • Travel & lodging$3,4186%
  • Food & beverage$3,0085%
  • Education$100%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)91$55,583
AbbVie(2 entities)5$337
Coopervision Inc.1$112
Eyevance Pharmaceuticals LLC2$47
Conmed Corporation1$38
Sun Pharmaceutical Industries Inc.1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$56,136 in reported general payments places this provider in the 95th percentile of 21 ophthalmic plastic and reconstructive surgery providers in Colorado.

See all ophthalmic plastic and reconstructive surgery providers in Colorado

Medicare billing

Part B allowed, 2024
$199,789
Medicare patients
362
Services billed
2,276

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TepezzaTeprotumumab-Trbw14$707,292
ErythromycinErythromycin Base396$4,505
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha135$1,482
Prednisolone Acetate37$1,371
Tramadol Hcl356$1,153
Cephalexin34$365
Doxycycline Hyclate14$172
Methylprednisolone21$76
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim14$72

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenTepezza$55,583$707,29214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 21 ophthalmic plastic and reconstructive surgery providers in Colorado.

Other ophthalmic plastic and reconstructive surgery in Edwards

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →